EGFR and lung carcinoma: Although our results did not show statistical significance, which may attribute to the small sample size of this subgroup and possible different role for each antibody in such patients, we think that as a potential stratification biomarker, TAAbs, not limited to these 5 TAAbs in the present study, is worthy of further large-scale studies in EGFR mutant lung cancer patients.